Found 3 hits for monomerid = 50199493 Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
Glucagon receptor
(Homo sapiens (Human)) | BDBM50199493
(1-(N-((1r,4r)-4-tert-butylcyclohexyl)-2-(4-(triflu...)Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(C1CCc2cc(ccc12)C(=O)Nc1nnn[nH]1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |w:11.11,wU:7.10,wD:4.3,(23.62,-41.57,;23.63,-40.04,;25.17,-40.04,;22.09,-40.03,;23.64,-38.5,;24.97,-37.73,;24.98,-36.18,;23.65,-35.42,;22.31,-36.19,;22.3,-37.72,;23.65,-33.88,;24.99,-33.11,;25.31,-31.61,;27.17,-31.64,;27.64,-33.1,;28.97,-33.86,;28.98,-35.41,;27.65,-36.18,;26.31,-35.41,;26.32,-33.88,;30.32,-36.18,;30.32,-37.72,;31.65,-35.41,;32.98,-36.17,;33.15,-37.7,;34.65,-38.02,;35.42,-36.68,;34.39,-35.54,;22.32,-33.11,;22.32,-31.57,;20.99,-33.88,;19.65,-33.11,;18.31,-33.89,;16.98,-33.11,;16.98,-31.57,;15.65,-30.8,;15.64,-29.26,;15.63,-27.72,;17.18,-29.25,;14.1,-29.27,;18.3,-30.8,;19.64,-31.56,)| Show InChI InChI=1S/C30H35F3N6O3/c1-29(2,3)21-8-10-22(11-9-21)39(26(40)16-18-4-12-23(13-5-18)42-30(31,32)33)25-15-7-19-17-20(6-14-24(19)25)27(41)34-28-35-37-38-36-28/h4-6,12-14,17,21-22,25H,7-11,15-16H2,1-3H3,(H2,34,35,36,37,38,41)/t21-,22-,25? | PDB MMDB
UniProtKB/SwissProt
B.MOAD antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Patents
Similars
| Article PubMed
| n/a | n/a | 67 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Research Laboratories
Curated by ChEMBL
| Assay Description Antagonist activity at human glucagon receptor transfected in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation |
Bioorg Med Chem Lett 17: 587-92 (2007)
Article DOI: 10.1016/j.bmcl.2006.11.014 BindingDB Entry DOI: 10.7270/Q2N58M0Q |
More data for this Ligand-Target Pair | |
Gastric inhibitory polypeptide receptor
(Homo sapiens (Human)) | BDBM50199493
(1-(N-((1r,4r)-4-tert-butylcyclohexyl)-2-(4-(triflu...)Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(C1CCc2cc(ccc12)C(=O)Nc1nnn[nH]1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |w:11.11,wU:7.10,wD:4.3,(23.62,-41.57,;23.63,-40.04,;25.17,-40.04,;22.09,-40.03,;23.64,-38.5,;24.97,-37.73,;24.98,-36.18,;23.65,-35.42,;22.31,-36.19,;22.3,-37.72,;23.65,-33.88,;24.99,-33.11,;25.31,-31.61,;27.17,-31.64,;27.64,-33.1,;28.97,-33.86,;28.98,-35.41,;27.65,-36.18,;26.31,-35.41,;26.32,-33.88,;30.32,-36.18,;30.32,-37.72,;31.65,-35.41,;32.98,-36.17,;33.15,-37.7,;34.65,-38.02,;35.42,-36.68,;34.39,-35.54,;22.32,-33.11,;22.32,-31.57,;20.99,-33.88,;19.65,-33.11,;18.31,-33.89,;16.98,-33.11,;16.98,-31.57,;15.65,-30.8,;15.64,-29.26,;15.63,-27.72,;17.18,-29.25,;14.1,-29.27,;18.3,-30.8,;19.64,-31.56,)| Show InChI InChI=1S/C30H35F3N6O3/c1-29(2,3)21-8-10-22(11-9-21)39(26(40)16-18-4-12-23(13-5-18)42-30(31,32)33)25-15-7-19-17-20(6-14-24(19)25)27(41)34-28-35-37-38-36-28/h4-6,12-14,17,21-22,25H,7-11,15-16H2,1-3H3,(H2,34,35,36,37,38,41)/t21-,22-,25? | PDB MMDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Patents
Similars
| Article PubMed
| n/a | n/a | 118 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Research Laboratories
Curated by ChEMBL
| Assay Description Antagonist activity at human GIP receptor transfected in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation |
Bioorg Med Chem Lett 17: 587-92 (2007)
Article DOI: 10.1016/j.bmcl.2006.11.014 BindingDB Entry DOI: 10.7270/Q2N58M0Q |
More data for this Ligand-Target Pair | |
Glucagon receptor
(Homo sapiens (Human)) | BDBM50199493
(1-(N-((1r,4r)-4-tert-butylcyclohexyl)-2-(4-(triflu...)Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(C1CCc2cc(ccc12)C(=O)Nc1nnn[nH]1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |w:11.11,wU:7.10,wD:4.3,(23.62,-41.57,;23.63,-40.04,;25.17,-40.04,;22.09,-40.03,;23.64,-38.5,;24.97,-37.73,;24.98,-36.18,;23.65,-35.42,;22.31,-36.19,;22.3,-37.72,;23.65,-33.88,;24.99,-33.11,;25.31,-31.61,;27.17,-31.64,;27.64,-33.1,;28.97,-33.86,;28.98,-35.41,;27.65,-36.18,;26.31,-35.41,;26.32,-33.88,;30.32,-36.18,;30.32,-37.72,;31.65,-35.41,;32.98,-36.17,;33.15,-37.7,;34.65,-38.02,;35.42,-36.68,;34.39,-35.54,;22.32,-33.11,;22.32,-31.57,;20.99,-33.88,;19.65,-33.11,;18.31,-33.89,;16.98,-33.11,;16.98,-31.57,;15.65,-30.8,;15.64,-29.26,;15.63,-27.72,;17.18,-29.25,;14.1,-29.27,;18.3,-30.8,;19.64,-31.56,)| Show InChI InChI=1S/C30H35F3N6O3/c1-29(2,3)21-8-10-22(11-9-21)39(26(40)16-18-4-12-23(13-5-18)42-30(31,32)33)25-15-7-19-17-20(6-14-24(19)25)27(41)34-28-35-37-38-36-28/h4-6,12-14,17,21-22,25H,7-11,15-16H2,1-3H3,(H2,34,35,36,37,38,41)/t21-,22-,25? | PDB MMDB
UniProtKB/SwissProt
B.MOAD antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Patents
Similars
| Article PubMed
| n/a | n/a | 4.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Research Laboratories
Curated by ChEMBL
| Assay Description Displacement of [125]glucagon from human glucagon receptor expressed in CHO cells |
Bioorg Med Chem Lett 17: 587-92 (2007)
Article DOI: 10.1016/j.bmcl.2006.11.014 BindingDB Entry DOI: 10.7270/Q2N58M0Q |
More data for this Ligand-Target Pair | |